MarketCap
Facebook
X
Telegram
Arena Pharmaceuticals Operating Cycle | ARNA
Annual Operating Cycle Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 8.16 K | 410 | 157 | 34.8 | 174 | 381 | 580 | 790 | 643 | 58.9 | 38.4 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.16 K | 34.8 | 1.04 K |
Quarterly Operating Cycle Arena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 335 | 50.9 | 119 | 219 | 0.47 | 53.7 | 130 | 116 | 194 | 14 | 89.1 | 113 | 80.5 | 13.7 | 95.6 | 193 | 116 | 58.1 | 49.3 | 49 | 32.2 | 36.9 | 41.5 | 26.5 | 95.8 | 148 | 270 | 14 | 311 | 262 | 341 | 23.1 | 128 | 26.7 | 16 | 17 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 341 | 0.47 | 108 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioXcel Therapeutics
BTAI
|
1.66 K | $ 0.07 | 9.81 % | $ 855 K |  USA |
 |
Navidea Biopharmaceuticals
NAVB
|
54.7 K | - | -2.99 % | $ 2.47 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Insmed Incorporated
INSM
|
400 | $ 120.63 | 0.95 % | $ 24 B | USA |
 |
Novan
NOVN
|
234 | - | -24.84 % | $ 2.64 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
bluebird bio
BLUE
|
180 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
257 | - | - | $ 13.6 B | USA |
 |
Marinus Pharmaceuticals
MRNS
|
59.8 | - | - | $ 29.6 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-65.8 | - | -1.56 % | $ 12.3 M | USA |
 |
CASI Pharmaceuticals
CASI
|
189 | - | - | $ 35.4 M | USA |
 |
Sigilon Therapeutics
SGTX
|
31.4 | - | - | $ 728 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Revance Therapeutics
RVNC
|
30.4 | - | - | $ 309 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
492 | $ 4.86 | 1.04 % | $ 787 M | USA |
 |
Epizyme
EPZM
|
47.2 | - | - | $ 249 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
214 | - | - | $ 4.55 M |  Irlanda |
 |
NGM Biopharmaceuticals
NGM
|
18.4 | - | - | $ 127 M | USA |
 |
9 Meters Biopharma
NMTR
|
111 | - | -42.97 % | $ 1.05 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
scPharmaceuticals
SCPH
|
447 | - | - | $ 218 M | USA |
 |
Athersys
ATHX
|
73 | - | 3.77 % | $ 22.4 M | USA |
 |
Liquidia Corporation
LQDA
|
36.8 | $ 55.17 | 7.32 % | $ 4.75 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
361 | $ 317.17 | 0.96 % | $ 6.13 B | USA |
 |
Global Blood Therapeutics
GBT
|
5.46 K | - | - | $ 4.62 B | USA |
 |
MannKind Corporation
MNKD
|
457 | $ 4.18 | -1.3 % | $ 1.28 B | USA |
 |
Merck & Co.
MRK
|
204 | $ 147.17 | -0.57 % | $ 368 B | USA |
 |
NanoString Technologies
NSTG
|
311 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
598 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
125 | - | -29.58 % | $ 126 M | USA |